Comparison · NCT04979442-9bd328f7
Milademetan vs Trabectedin: Number of Participants With Treatment-emergent Adverse Events Until Approximately 30 Days After the Last Study Drug
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Milademetan vs Trabectedin: Number of Participants With Treatment-emergent Adverse Events Until Approximately 30 Days After the Last Study Drug. Trial comparisons, record NCT04979442-9bd328f7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04979442-9bd328f7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.957 | 1 | wilson | |
| Risk in group 2 | 0.987 | 0.932 | 0.998 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0127 | -0.0314 | 0.0683 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.988 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Milademetan than on Trabectedin | 79 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Milademetan | Milademetan was supplied as 30- and 100-mg strength capsules. The starting dose of milademetan 260 mg administered once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle. | 86 | 86 | OG000 |
| Group 2 | Trabectedin | Trabectedin was provided as a sterilized lyophilized powder in single, 1-mg dose vials. Trabectedin was administered per the manufacturer's instructions at 1.5 mg/m2 body surface area (BSA) as a 24-hour IV infusion, every 3 weeks (ie, 21-day cycles) through a central venous line. | 78 | 79 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment-emergent Adverse Events Until Approximately 30 Days After the Last Study Drug
- Description
All AEs were collected from the initiation of study treatment until 30 days after the last administration study drug or until initiation of another anticancer therapy, whichever came first; up to 26.6 months.
- Time frame
- From first dose date to 30 days after the last dose date or the primary study completion date whichever came first; up to 26.6 months.
- Population
- All AEs were collected from the initiation of study treatment until 30 days after the last administration study drug or until initiation of another anticancer therapy, whichever came first.
Source ClinicalTrials.gov
Trial
- Title
- Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
- NCT number
- NCT04979442
- Phases
- PHASE3
- Conditions
- Dedifferentiated Liposarcoma
- Interventions
- RAIN-32, Trabectedin
- Lead sponsor
- Rain Oncology Inc
- Results first posted
- 2025-01-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04979442?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04979442-9bd328f7